LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Biocryst Pharmaceuticals Inc.
Headquarters:
Durham, NC, United States of America
Website:
http://www.biocryst.com
Year Founded:
1986
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Jon P. Stonehouse
Number Of Employees:
580
Enterprise Value:
$2,074,711,920
PE Ratio:
-17.93
Exchange/Ticker 1:
NASDAQ:BCRX
Exchange/Ticker 2:
N/A
Latest Market Cap:
$1,611,081,600
BioCentury
|
Mar 5, 2025
Management Tracks
CFO Anthony Doyle resigns at Biocryst
Plus: Greenside succeeds CEO Mark DePristo at Bighat, and updates from Be Biopharma, 3t and Imugene
Read More
BioCentury
|
Mar 31, 2023
Management Tracks
Amarin CEO Mikhail resigns, Kostas named chair
Plus: BioCryst appoints Hutson chair and updates from Flare, Mytide and TScan
Read More
BioCentury
|
Dec 16, 2022
Finance
Dec. 15 Quick Takes: Enlaza debuts with $61M, covalent targeting biologics platform
Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more
Read More
BioCentury
|
Sep 17, 2022
Product Development
HAE data clear Intellia’s path for liver knockout indications
The next test for Intellia will be whether it can achieve the same success with gene insertions
Read More
BioCentury
|
Sep 15, 2022
Management Tracks
New roles for Sheridan, Arnold at BioCryst
Plus Maltais joins XNK as CSO, and updates from HaYa, Ratio and more
Read More
BioCentury
|
Aug 16, 2022
Management Tracks
Simcha hires CEO, expands research agreement
Plus Integra’s Caruso passes away and updates from Ambrx, Cullinan, Zephyr, South Rampart and more
Read More
BioCentury
|
Aug 5, 2022
Finance
Aug. 4 Quick Takes: Forbion, Sofinnova lead F2G’s $70M financing
Plus newco emerges from Daley lab and updates Lilly, Pfizer, Regeneron, Arucs-Gilead, Travere, BioCryst and more
Read More
BioCentury
|
Apr 9, 2022
Finance
April 8 Quick Takes: Kaleido winding down operations
Plus: BioCryst loses $1.2B in market cap after pivotal pause and the latest in CEPI investments and more
Read More
BioCentury
|
Dec 3, 2021
Management Tracks
Sniecinski becomes CBO at Praxis
Plus: Monte Rosa, Taro, Point, Harbour and more
Read More
BioCentury
|
Nov 23, 2021
Product Development
Nov. 22 Quick Takes: GSK, Arrowhead in deal for NASH candidate
Plus Zenas-Xencor, BioCryst, Deciphera, bluebird, Exelixis and more
Read More
Items per page:
10
1 - 10 of 375